Unknown

Dataset Information

0

An open-label randomized, controlled trial of the effect of lopinavir and ritonavir, lopinavir and ritonavir plus interferon-β-1a, and hydroxychloroquine in hospitalized patients with COVID-19: final results.

ABSTRACT:

SUBMITTER: Ader F 

PROVIDER: S-EPMC9076583 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

An open-label randomized, controlled trial of the effect of lopinavir and ritonavir, lopinavir and ritonavir plus interferon-β-1a, and hydroxychloroquine in hospitalized patients with COVID-19: final results.

Ader Florence F  

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 20220507 9

Similar Datasets

Unknown An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19.
| S-EPMC8149166 | biostudies-literature
Unknown No Efficacy of the Combination of Lopinavir/Ritonavir Plus Hydroxychloroquine Versus Standard of Care in Patients Hospitalized With COVID-19: A Non-Randomized Comparison.
| S-EPMC8100580 | biostudies-literature
Unknown Camostat Mesylate Versus Lopinavir/Ritonavir in Hospitalized Patients With COVID-19-Results From a Randomized, Controlled, Open Label, Platform Trial (ACOVACT).
| S-EPMC9354138 | biostudies-literature
Unknown Efficacy and safety of favipiravir plus interferon-beta versus lopinavir/ritonavir plus interferon-beta in moderately ill patients with COVID-19: A randomized clinical trial.
| S-EPMC9088571 | biostudies-literature
Unknown Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
| S-EPMC7535623 | biostudies-literature
Unknown Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial.
| S-EPMC7211500 | biostudies-literature
Unknown A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.
| S-EPMC7121492 | biostudies-literature
Unknown Comparing albuvirtide plus ritonavir-boosted lopinavir regimen to two nucleotide reverse transcriptase inhibitors plus ritonavir-boosted lopinavir in HIV-infected individuals who failed initial treatment: a retrospective comparative cohort study.
| S-EPMC9652537 | biostudies-literature
Unknown Combination of (interferon beta-1b, lopinavir/ritonavir and ribavirin) versus favipiravir in hospitalized patients with non-critical COVID-19: A cohort study.
| S-EPMC8191942 | biostudies-literature
Unknown Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial.
| S-EPMC8274471 | biostudies-literature